Insider Selling: Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells 5,000 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total value of $244,000.00. Following the sale, the director now owns 31,471 shares of the company’s stock, valued at approximately $1,535,784.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Amphastar Pharmaceuticals Trading Down 4.7 %

NASDAQ:AMPH opened at $45.48 on Thursday. The company has a current ratio of 3.43, a quick ratio of 2.61 and a debt-to-equity ratio of 0.82. The firm’s 50 day moving average is $48.42 and its 200 day moving average is $44.34. Amphastar Pharmaceuticals, Inc. has a 12 month low of $36.56 and a 12 month high of $65.92. The stock has a market capitalization of $2.19 billion, a PE ratio of 15.16, a price-to-earnings-growth ratio of 0.92 and a beta of 0.82.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Silvercrest Asset Management Group LLC increased its stake in shares of Amphastar Pharmaceuticals by 35.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock worth $4,937,000 after purchasing an additional 29,182 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Amphastar Pharmaceuticals during the 3rd quarter worth about $11,070,000. Intech Investment Management LLC bought a new position in Amphastar Pharmaceuticals in the 2nd quarter worth about $426,000. Granite Investment Partners LLC grew its holdings in Amphastar Pharmaceuticals by 12.7% during the 2nd quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock valued at $15,901,000 after buying an additional 44,744 shares in the last quarter. Finally, 1620 Investment Advisors Inc. bought a new stake in shares of Amphastar Pharmaceuticals during the second quarter valued at about $93,000. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Wall Street Analyst Weigh In

AMPH has been the topic of a number of analyst reports. Needham & Company LLC restated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Finally, Piper Sandler cut their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.